Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1).
BACKGROUND
To what degree the associations between PCa risk and family history of prostate cancer (PCa) and/or breast cancer (BCa) are attributable to screening biases is unclear. We examined these questions within the REDUCE study, where biopsies were largely independent of prostate specific antigen (PSA) minimizing screening biases.


METHODS
Data were from REDUCE, which tested dutasteride 0.5 mg daily for PCa risk reduction in men with PSA 2.5-10.0 ng mL(-1) and a negative prestudy biopsy. Among men undergoing at least one on-study biopsy with complete data (n = 6415; 78.1%), the association between family history and PCa risk was tested using multivariate logistic regression adjusting for clinicodemographic characteristics.


RESULTS
A family history of PCa alone was associated with increased PCa diagnosis (OR: 1.47, 95%CI: 1.22-1.77). In North America, PCa family history was not related to PCa diagnosis (OR: 1.02, 95%CI: 0.73-1.44), whereas outside North America, PCa family history was significantly related to diagnosis (OR: 1.72, 95%CI: 1.38-2.15) (P-interaction = 0.01). A family history of both PCa and BCa (OR: 2.54, 95%CI: 1.72-3.75) but not BCa alone (OR: 1.04, 95%CI: 0.84-1.29) was associated with increased PCa risk versus no family history and irrespective of geographical region.


CONCLUSIONS
In REDUCE, PCa family history was significantly related to PCa diagnosis, although only for men outside North America. The presence of both PCa and BCa family history significantly increased risk versus PCa family history alone, irrespective of geographical region. Ultimately, our observations may support the need for changes in how we address family history in terms of both risk of PCa diagnosis and general risk stratification.
Surgery Section, Durham VA Medical Center, Durham, NC, USA.
J-A
JA
Thomas
L
L
Gerber
D M
DM
Moreira
R J
RJ
Hamilton
L L
LL
Bañez
R
R
Castro-Santamaria
G L
GL
Andriole
W B
WB
Isaacs
J
J
Xu
S J
SJ
Freedland
D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage; D000368:Aged; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D001378:Azasteroids / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000235:genetics*; D015331:Cohort Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D000068538:Dutasteride; D005260:Female; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008487:Medical History Taking; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000235:genetics* / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors
D058891:5-alpha Reductase Inhibitors; D016588:Anticarcinogenic Agents; D001378:Azasteroids; D000068538:Dutasteride